Drs Arlene O. Siefker-Radtke and Scott T. Tagawa comment on opportunities for treating metastatic urothelial cancer with FGFR targeted therapies based on current trends in molecular testing and emerging therapies.
EP. 2: Tissue and Liquid Biopsies in Metastatic Urothelial Cancer
A discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).